If you say so but not likely IMO. My guess is the FDA will prefer to see universal approval over something that helps a much lesser group. CRTX will be the one to watch and it reads out in about 6 weeks. 600+ patients, and should either almost universally work or not at all based on the MOA. If in a few months we don't find the FDA is allowing for a provisional approval while they run an additional trial confirmation trial, the rest of the AD space for mild to moderate will realize what they will likely have to do in terms of trials. The likelihood is we already know.
Market Data 
Markets 
AI
